SCHEMBL5873423

SCHEMBL5873423

CC(Oc1cc(NC(=O)c2cccnc2Nc2ccc3cn[nH]c3c2)ccc1C(C)(C)C)C1CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.51
TRPV1 Q8NER1 4/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 3/20 0.37
KDM4E B2RXH2 1/20 0.37
SYK P43405 3/20 0.37
BTK Q06187 2/20 0.37
MET P08581 1/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PTGES O14684 2/20 0.36
EP300 Q09472 1/20 0.36
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13867926 0.88 KDR (0.51) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL3901456 0.88 KDR (0.51) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL5873426 0.87 KDR (0.51) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL4554949 0.81 KDR (0.52) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL631358 0.80 KDR (0.55) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL3901531 0.80 KDR (0.52) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL3903905 0.78 KDR (0.55) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL13867895 0.78 KDR (0.51) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL3892509 0.77 KDR (0.54) KDRTRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL3893122 0.77 KDR (0.54) KDRTRPV1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105682-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2006-09-12 US disclosed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195230-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KDR 13/4885TRPV1 3811/4885NPC1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.